Sibylle Loibl
A5087559224- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Breast Implant and Reconstruction
- Caveolin-1 and cellular processes
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
German Breast group
2016-2025
Cancer Clinic
2025
NSABP Foundation
2012-2025
National Cancer Institute
2025
National Center for Tumor Diseases
2013-2025
Helios Hospital Berlin-Buch
2010-2025
Cardiovascular Center Bethanien
2010-2024
Goethe University Frankfurt
2013-2024
University Hospital Frankfurt
2004-2024
Krankenhaus Bethanien
2010-2024
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity early studies.
PURPOSE Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated prespecified hypothesis that presence lymphocytic infiltrate in cancer tissue predicts response neoadjuvant chemotherapy. METHODS We intratumoral and stromal lymphocytes total 1,058 pretherapeutic breast core biopsies from two anthracycline/taxane-based studies (GeparDuo, n = 218, training cohort; GeparTrio, 840, validation cohort). Molecular parameters lymphocyte...
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 CDK6), which promote progression from the G1 phase to S cell cycle. We assessed efficacy palbociclib (an inhibitor CDK4 CDK6) fulvestrant in advanced cancer.This 3 study involved 521 patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative that had relapsed or progressed during prior endocrine therapy. randomly assigned a 2:1 ratio receive placebo...
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed...
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which expressed in majority cancers, coupled to SN-38 (topoisomerase I inhibitor) through proprietary hydrolyzable linker.
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Neoadjuvant (primary systemic) treatment is the standard for locally advanced breast cancer and a option primary operable disease. Because of new treatments understandings cancer, however, recommendations published in 2003 regarding neoadjuvant disease required updating. Therefore, second international panel representatives number clinical research groups was convened September 2004 to update these recommendations. As part this effort, data date were reviewed critically indications newly defined.
Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast International 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression. Methods Patients with HER-2–positive cancer that progresses during were randomly assigned to receive capecitabine (2,500 mg/m body-surface area on days 1 through 14 [1,250 semi-daily]) alone or continuation of (6...